Podcasts about Progression

Don't go back please that's it don't go back progress do not decline ..

In dieser Episode des Calisthenics Podcasts spricht Coach Flex über einen der bekanntesten und gleichzeitig anspruchsvollsten Skills im Street Workout: den Front Lever. Warum fällt dieser Skill so vielen Athleten schwer? Und welche Fehler machen vor allem Anfänger beim Training?Coach Flex teilt seine persönliche Geschichte – vom Einstieg ins Calisthenics wegen Rückenproblemen bis hin zum sicheren Front Lever. Außerdem erklärt er die 5 wichtigsten Learnings, die er gerne schon vor 12 Jahren gekannt hätte. Dabei geht es unter anderem um typische Trainingsfehler, die richtige Nutzung von Widerstandsbändern, sinnvolle Progressionen und vor allem um die entscheidende Frage: Wie stark musst du wirklich sein, um einen Front Lever zu schaffen?Ein besonderes Highlight dieser Folge ist die Analyse realer Trainingsdaten aus dem Calisthenics Coaching: Laut aktuellen Auswertungen schaffen die meisten Athleten den Front Lever erst, wenn sie etwa 70 % ihres Körpergewichts im Chin-Up ziehen können. Was das konkret für dein Training bedeutet und wie du deine Progression sinnvoll aufbaust, erfährst du in dieser Episode.Egal ob du gerade erst mit Calisthenics anfängst, schon länger trainierst oder gezielt Skills wie Front Lever, Muscle-Up oder Dragon Flag lernen möchtest – diese Folge liefert dir wertvolle Einblicke für effektiveres Training.Themen dieser Folge:Was der Front Lever wirklich istTypische Fehler beim Front Lever TrainingDie richtige Position für WiderstandsbänderWarum reine Skill-Progressionen oft nicht ausreichenWie viel Zugkraft du für den Front Lever brauchstWarum Krafttraining der Schlüssel zum Erfolg istTipps für Anfänger und Fortgeschrittene im CalisthenicsWenn du dein Training strukturierter angehen willst und schneller Fortschritte machen möchtest, kannst du dir ein kostenloses Beratungsgespräch sichern. Gemeinsam schauen wir uns deine aktuelle Situation, dein Training und deine Ziele an.

Message from Rev. Jason Palacio on March 8, 2026

Pour ceux qui souhaitent rejoindre la #TribuESOA c'est par ici : https://bit.ly/TribuESOAVoici ce que vous obtenez en rejoignant la tribu ESOA :✅ Echangez quotidiennement avec Kahi, Moulaye pour co-construire le podcast mais aussi sur vos difficultés, interrogations et l'actualité en toute simplicité !✅ Accès d'un an à la communauté privée ESOA (La tribe): un réseau exclusif de 200 membres dans 15 pays entrepreneurs et professionnels africains partout dans le monde pour développer votre réseau, échanger, et vous entraider.✅ Accès à tous nos Masterminds, Book Clubs, Meetups, et événements ESOA exclusifs et à tarifs réduits: participez à des sessions interactives avec Kahi, Moulaye, et des experts invités pour enrichir vos connaissances et votre réseau.✅ Le Template du Life Plan de Moulaye et Kahi: des outils concrets pour clarifier vos objectifs professionnels et personnels, adaptés à tous les profils.✅ Le Replay unique du Mastermind du 18 Décembre “Construire son plan de vie”Un contenu exclusif pour vous guider dans la création de votre plan de vie et de carrière.---------Le Podcast "#Entrepreneur State Of Africa" dit tout haut ce que les #entrepreneurs pensent tout bas, avec Kahi Lumumba (Co-Founder & CEO Totem Experience, Adicomdays) et Moulaye Tabouré (Co-Founder & CEO de ANKA (ex-Afrikrea) ). -----Ce podcast est produit par Totem Factory by Totem Experience que vous pouvez joindre pour tous vos besoins de production

Our Wednesday Night Worship Experience streamed live on March 4th, 2026. Experience life with people, power, and purpose. Connect with us! https://www.kcalaska.com/ https://www.facebook.com/kingschapel.alaska/ https://www.instagram.com/kingschapelalaska/ Give: https://www.kcalaska.com/give/

Ron nous raconte enfin son récit, et l'histoire nous mène jusqu'à Azkaban. BONUS: Le chapitre 1 du tome 1 de Narnia, l'expérience Cozy with Brina, disponible sur Patreon exlusivement.Progression de lecture: 72%Fanfiction en anglaisFanfiction en françaisPatreonBuy me a CoffeeSpotifyLogo par Sabrina CayerInstagram: ⁠@cozywithbrinaMusique: The Streets of Baerlon, par Ivan Duch (https://ivanduch.com)

On nous répète qu'un bon manager doit être patient. Compréhensif. Bienveillant.Mais à partir de quand la patience devient-elle contre-productive ?Dans cet épisode, je vous propose une réflexion essentielle : la patience est une qualité managériale… à condition qu'elle soit accompagnée de clarté, d'exigence et de conséquences.Parce que la vraie question n'est pas “suis-je patient ?”Mais “ma patience sert-elle encore la progression de l'équipe ?”NOUVEAU : retrouvez moi sur WhatsApp sur la chaîne Happy Work... pas de spam, c'est gratuit et il n'y a que du feelgood !!! : https://whatsapp.com/channel/0029VbBSSbM6BIEm0yskHH2gEt pour retrouver tous mes contenus, tests, articles, vidéos : www.gchatelain.comDÉCOUVREZ MON AUTRE PODCAST, HAPPY MOI, LE PODCAST POUR PRENDRE SOIN DE VOUS, VRAIMENT: lnk.to/sT70cYmanagementleadershipmanagement d'équipeexigencebienveillanceperformance collectiveresponsabilité managerHappy Work00:00 Introduction 00:34 La patience comme investissement 01:41 Progression ou répétition ? 02:38 Compétence ou attitude ? 04:00 Soutien et conséquences 05:24 Ce qu'il faut retenir de cet épisodeSoutenez ce podcast http://supporter.acast.com/happy-work. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Join the email list to get a FREE private finger training clinic with Dr. Tyler Nelson (normally $10) www.thestruggleclimbingshow.com/strong   Support the Show on Patreon Get access to all Pro Clinics, bonus episodes, and more. https://www.patreon.com/thestruggleclimbingshow   - Elite climber Mike Boyd explores: The formula for rapid learning  His biggest mistake when he was a new climber How to get better at failure  Avoiding “junk mileage” when learning a new skill The 40-minute rule for optimized learning  Why coaches don't like shortcuts (and why we should anyway) Stealing knowledge from fellow climbers  Trying the Dave McLeod diet Refusing to say “I'm too short” - BIG THANKS TO THE AMAZING SPONSORS OF THE STRUGGLE WHO LOVE ROCK CLIMBING AS MUCH AS YOU DO: PhysiVantage: the official climbing-nutrition sponsor of The Struggle. Train harder, recover faster, and feel better than ever. I love all their stuff! Use code STRUGGLE15 at checkout for 15% off your full-priced nutrition order. Kilter: Award winning, adjustable, light-up boards. I'm training on the Homewall Full Ride, and if you're psyched to join me then use code STRUGGLE at checkout when you build your board, and you'll score up to $1000 off plus a free gift pack let's goooo! And check out ALL the show's awesome sponsors and exclusive deals at thestruggleclimbingshow.com/deals   - Follow Mike on IG @mikeboydvideo and on YT /@mikeboyd and /@mikeboydclimbs - Shoutout to Aiden Schlatter for supporting at the Hero level on Patreon. A hero indeed! - Here are some AI generated show notes (hopefully the robots got it right) 00:00 Welcome and Learning Dip 00:41 Meet Mike Boyd 04:18 Climbing Setup and Psyche 17:35 Struggle Mindset Origins 27:47 Learning Framework and Breaks 32:57 Training Diary Metrics 33:51 Self Coaching vs Mentors 38:19 Keeping the Psych Alive 41:12 Weekly Climbing Plan 57:25 Nutrition Weight Strategy 01:09:41 Resting Like A Pro 01:10:41 Climbing In Gears 01:14:18 Projecting And Send Blues 01:18:21 Fear Of Falling Tools 01:32:02 Creative Goals And Wrap - Follow along on Instagram @thestruggleclimbingshow and YouTube /@thestruggleclimbingshow - The Struggle is carbon-neutral in partnership with The Honnold Foundation, whose mission is to promote solar energy for a more equitable world. - This show is produced and hosted by Ryan Devlin, and edited by Glen Walker. The Struggle is a proud member of the Plug Tone Audio Collective, a diverse group of the best, most impactful podcasts in the outdoor industry. - The struggle makes us stronger! I hope your training and climbing are going great.  - And now here are some buzzwords to help the almighty algorithm get this show in front of people who love to climb: rock climbing, rock climber, climbing, climber, bouldering, sport climbing, gym climbing, how to rock climb, donuts are amazing. Okay, whew, that's done. But hey, if you're a human that's actually reading this, and if you love this show (and love to climb) would you think about sharing this episode with a climber friend of yours? And shout it out on your socials? I'll send you a sticker for doing it. Just shoot me a message on IG – thanks so much! 

The Journal of Rheumatology's Editor-in-Chief Earl Silverman discusses this month's selection of articles that are most relevant to the clinical rheumatologist. Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events - doi.org/10.3899/jrheum.2025-0446 Risk of Spondyloarthritis in Patients With Inflammatory Bowel Disease Receiving Treatment With Biologics or Janus Kinase Inhibitors - doi.org/10.3899/jrheum.2024-1279 The Renal Activity Index for Lupus: Validation for Prediction of Kidney Inflammation in Adult Patients With Lupus Nephritis - doi.org/10.3899/jrheum.2025-0504 Association of Frailty With Risk of Osteoarthritis Development, Progression, and Worse Clinical Outcomes in Older Adults - doi.org/10.3899/jrheum.2025-0578 Effectivity and Safety of Febuxostat in Reducing Serum Urate in Gout Patients With Chronic Kidney Disease: A Prospective Multicenter ULTRA Registry Study - doi.org/10.3899/jrheum.2025-0881

On episode 736 of the 40+ Fitness Podcast, host Coach Allan sits down with returning guest David Frost, NFPT Certified Master Fitness Trainer, champion masters rower, and author of Strong to Save: Your Gen X Imperative to Die Harder and Later. Together, they dive into what it really takes for Gen Xers—and anyone over 40—to extend not just their lifespan, but their healthspan by training smarter and embracing functional fitness. You'll hear David Frost break down his practical framework of moving from "decent" to "good" to "great" when it comes to strength and wellness, discuss the crucial difference between healthspan and lifespan, and challenge popular anti-aging and "super ager" myths with his no-nonsense philosophy on aging well. Coach Allan and David Frost also get real about the importance of sleep, nutrition, and recovery, and share actionable strategies to enhance your quality of life right now—regardless of where you're starting. If you're curious about how to unlock more energy, strength, and resilience as you get older, and want to take away powerful insights you can put into action today, this episode is for you. Time Stamps: 03:39 Invest in Your Future Health 07:04 Get Decent, Live Longer 12:20 Progression and Healthy Aging 16:48 Fitness Years Over Calendar Years 18:34 Heart Health and Superaging Insights 21:11 Essential 5 Movements for Fitness 25:56 Exercise, Aging, and Joint Care 29:37 Training Power for Real Life 30:55 Rowing, Power, and Endurance 36:39 Sleep, Health, and Recovery Insights 39:12 Competitive Approach to Activity Tracking 42:16 Be a Student, Start Now https://wellpastforty.com 

Doop and Dave are in the dugout again this week to discuss how their saves have progressed since the last episode. 5 Star Potential - www.twitter.com/5starpod - www.5starpotential.comTikTok - https://www.tiktok.com/@5starpodDaveAzzopardi - Twitch: www.twitch.tv/daveazzopardi Twitter: twitter.com/daveazzopardiFMDoop - Twitter: www.twitter.com/fmdoop - Twitch: www.twitch.tv/doop

Jeremiah shares a guest interview he did on Lisa Franz's Nutrition & Life PodcastKEY TOPICS:How to structure a 12-18 month plan for clients aiming for both muscle gain and fat lossCommon mistakes during building phases, including exercise selection and intensity issuesHow to periodize nutrition with fat loss, building, maintenance, and reverse diet phasesPractical example: transitioning a client from fat loss to muscle building over a yearJeremiah's personal experience with physique changes, experimenting with fasting, and competing plansThe benefits of experimentation and self-tracking to optimize results and stay motivatedCHAPTERS:00:00 - Intro 02:17 - Jeremiah's recent travel experiences and personal life updates 04:20 - Key takeaways: building muscle, client physique gaps, and training improvements 06:20 - Visualizing physique goals and the importance of muscle development for definition 09:51 - The importance of training intensity and progressive overload for growth 10:43 - What is phasic nutrition periodization? How to cycle through phases effectively 12:02 - Structuring a year-long plan: fat loss, building, and maintenance phases 13:53 - Practical example: helping clients reach their physique goals with phased nutrition 14:19 - Assessing a client's current position and the importance of baseline establishment 16:16 - Hybrid approach: recomposition, ramping movement, and nutrition during initial phases 17:45 - Transitioning into dedicated fat loss and muscle-building phases 20:59 - Progression, tracking, and the scale's role in building phases for women 24:58 - Exercise selection, targeting specific muscles, and execution tips 30:55 - Importance of intensity, fatigue, and failure proximity 34:29 - Other fundamentals: hydration, sleep, and schedule management 38:56 - Jeremiah's personal physique journey, experimentation, and competition plans 44:14 - Recap of a year of strategic physique changes and experimentationLINKS:Apply for Coaching: https://ecs-coaching.super.site/Living Lean Podcast: https://www.buzzsprout.com/712032Follow Jeremiah on Instagram: https://www.instagram.com/jeremiahbair/Follow Andrea on Instagram: https://www.instagram.com/andirogersfit/Follow Natalie on Instagram: https://www.instagram.com/natalieatswell/Lisa's podcast: https://podcasts.apple.com/us/podcast/nutrition-life/id1649806306Lisa's IG: https://www.instagram.com/nutritioncoachingandlife/KEYWORDS:phasic nutrition, muscle building, training intensity, nutrition phases, coaching, fitness, health, bodybuilding, nutrition strategies, client coachingTo Apply For Coaching With Our Team: CLICK HERE

Torque and cadence are common features of cycling training programs, but how should you really train them to get the most out of your training? Peter Leo is a sports scientist and high-performance coach working across cycling (Team Jayco-Alula, Cycling Australia) and triathlon (coach of high-level short-course athletes), and since he's personally researched this topic, and applied it at the highest level, he's a perfect guest to answer this question. We also discuss training principles, including debunking some common misconceptions and mistakes made when applying training principles in practice.  HIGHLIGHTS AND KEY TOPICS:  The science behind the torque-cadence relationship Torque and cadence are performance limiters at different points on the power-duration curve Practical application of the science in different contexts (track and road cycling, short and long course triathlon), including specific workout examples Peter's view on three core training principles… Individualisation. What are the biggest factors behind needs to individualise training? Is individualisation overrated in certain contexts?  Specificity. Is there an over emphasis on race specificity, compared to maximising core physiological capacities and general skills?  Progression. What does effective progression really look like in triathlon and cycling training? Are amateur cyclists and triathletes adopting too aggressive progression rates?  Evaluating response to training, AI and coaching, and Peter's top tips for the listeners to improve their cycling and triathlon performance.  DETAILED EPISODE SHOWNOTES:  We have detailed shownotes for all of our episodes. The shownotes are basically the podcast episode in written form, that you can read in 5-10 minutes. They are not transcriptions, but they are also not just surface-level overviews. They provide detailed insights and timestamps for each episode, and are great especially for later review, after you've already listened to an episode.  The shownotes for today's episode can be found at https://scientifictriathlon.com/tts686/ LINKS AND RESOURCES:  Peter's ResearchGate Power profiling, critical power, and U23 cycling research with Peter Leo | EP#319 - Peter's previous appearance on That Triathlon Show (January 2022) Rethinking Endurance Training: Insights from Peter Leo - Peter's appearance on Joel Filliol's podcast WHAT SHOULD I LISTEN TO NEXT? If you enjoyed this episode, I think you'll love the following related episodes: Dan Lorang | EP#417 - Head of Performance (at the time) at team Bora-hansgrohe, and coach of athletes like Jan Frodeno, Lucy Charles-Barclay and Taylor Knibb, Dan needs no introduction.  Training Talk with Ben Day (Team BikeExchange) | EP#289 - Another coach straddling the cycling and triathlon worlds, Ben is (was, at the time) a coach at Team BikeExchange, and coach of professional long distance triathletes like Chris Leiferman. You can find our full episode archives here, where you can filter for categories such as Training, Racing, Science & Physiology, Swimming, Cycling, Running etc. You can also find separate archives for specific series of episodes I've done, specifically Q&A episodes, TTS Thursday episodes, and Beginner Tips episodes.  LEARN MORE ABOUT SCIENTIFIC TRIATHLON:  The Scientific Triathlon website is the home of That Triathlon Show and everything else that we do Contact us through our contact form or email me directly (note - email/contact form messages get responded to much more quickly than Instagram DMs) Subscribe to our Newsletter Follow us on Instagram Learn more about our coaching, training plans, and training camps. We have something to offer for everybody from beginners to professionals.  HOW CAN I SUPPORT THAT TRIATHLON SHOW (FOR FREE)?  I really appreciate you reading this and considering helping the show! If you love the show and want to support it to help ensure it sticks around, there are a few very simple things you can do, at no cost other than a minute of your time.  Subscribe to the podcast in your podcast app to automatically get all new episodes as they are released. Tell your friends, internet and social media friends, acquaintances and triathlon frenemies about the podcast. Word of mouth is the best way to grow the podcast by far!  Rate and review the podcast (ideally five stars of course!) in your podcast app of choice (Spotify and Apple Podcasts are the biggest and most important ones). Share episodes online and on social media. Share your favourite episodes in your Instagram stories, start a discussion about interesting episodes on forums, reference them in your blog or Substack.  SPONSORS:  Precision Fuel & Hydration produce our favourite gels, sports drinks, and electrolyte and carbohydrate products here at That Triathlon Show and Scientific Triathlon. Use the free Fuel & Hydration Planner to get a personalised plan for your carbohydrate, sodium and fluid intake in your next event, and get 15% off your first 2026 order by using the code TTS2026 at checkout. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Get Psyched, Lindsey connects her (slightly mischievous) love of embarrassment to one of the most influential relationship research programs of all time: the Love Lab led by John Gottman.Inside the famed Love Lab at the University of Washington, couples were observed to uncover what actually predicts long-term relationship success. The biggest predictor? Not grand gestures. Not passion. Not compatibility quizzes.It was how partners responded to bids for connection.Today the gals explore:

Pushing Forward with Alycia welcomes award-winning singer, songwriter, actor, writer, and Georgetown Law graduate James Ian, who lives with Spinal Muscular Atrophy (SMA) type 3. Alycia Anderson and James talk about meeting at New York Fashion Week 2024 during Runway of Dreams and what it meant to see disabled models represented on the runway. James shares how access barriers at Georgetown motivated him toward law school to fight for disability rights, and how experiences performing music—including falling on stage and disclosing his disability—helped him realize he could advocate through art. He also talks about his performance at the DRA Gala (Disability Rights Advocates) in a room that included Hillary Clinton, and discusses the limited opportunities for disabled musicians, widespread venue inaccessibility, and the extra labor of education and advocacy alongside creative work. James details SMA basics, how type 3 has progressed for him, and complications from his cervical stenosis surgery that led to C5 palsy, major loss of arm strength, requiring rehab and forcing him to relearn his body. This episode dives into so much more with reflections on grief, gratitude, learning to accept help and more on his songs including “Spaces,” “Lift Me Up” honoring Judy Heumann, and his collaboration “Unconditional Love” with disabled artist Tap Waters. What Shaped Our Dialogue ✨ When Advocacy Meets Artistry ⚖️ From Law to Lyrics

In ETP 211, we dig into Bryan's recent adventure into his intuitive training Bro Split, and whether ditching the logbook is a sign of experience or a terrible idea. We explore the argument between tracking vs “feeling”, break down the real nuances of progressive overload, and discuss why the stimulus derived might matter more than the absolute weight being used.We also cover how this training strategy might shift depending on where you are in your journey, and why the answers to some of the biggest questions in training aren't as settled as the fitness industry likes to pretend.Timestamps:00:00 Introduction to Intuitive Training02:58 Exploring the Bro Split and Recency Bias06:00 Mental State and Training Frequency Challenges09:00 Tracking Progress: Intuitive vs. Logbook14:41 The Nuances of Progressive Overload20:18 The Importance of Muscle Connection26:06 Beginners vs. Advanced Training Strategies29:49 Adjusting Weight for Optimal Progress33:56 The Importance of Structure for Beginners35:24 Seasonal Training Approaches38:48 Transitioning from Tracking to Intuitive Training42:31 The Role of Connection in Muscle Training52:57 Exploring the Unknowns of Progressive Overload Work 1:1 with Aaron ⬇️https://strakernutritionco.com/nutrition-coaching-apply-now/Done For You Client Check-In System for Coaches ⬇️https://strakernutritionco.com/macronutrient-reporting-check-in-template/Paragon Training Methods Programming ⬇️https://paragontrainingmethods.comFollow Bryan's Evolved Training Systems Programming ⬇️https://evolvedtrainingsystems.comFind Us on Social Media ⬇️IG | @Eat.Train.ProsperIG | @bryanboorsteinIG | @aaron_strakerYT | EAT TRAIN PROSPER PODCAST

L'attentat antisémite de Bondi, qui a endeuillé l'Australie le 14 décembre dernier, pourrait fracturer plus profondément le pays. Malgré une politique migratoire très stricte, l'Australie se faisait le champion du multiculturalisme. Ainsi, certains signes inquiètent : forte progression du parti d'extrême droite One Nation, progression des groupuscules néo-nazis, mais aussi une multiplication des actes racistes, ciblant en particulier la communauté musulmane. De notre correspondant à Sidney, À la mosquée de Lakemba, la plus grande d'Australie, située dans la banlieue ouest de Sydney, c'est la dernière prière du vendredi avant le début du ramadan. Cette année, le cœur n'est pas à la fête. La mosquée a reçu deux lettres de menaces en à peine dix jours et sa page Facebook est noyée sous les commentaires haineux et insultants.  D'après Jamal Kio, le porte-parole de l'association qui gère le lieu de culte, les fidèles aussi sont victimes de cette haine. « Certains se font insulter, d'autres se font cracher dessus et des femmes se font arracher leur voile, témoigne-t-il. Cette forme de racisme direct, qui devient violent, est inquiétante. »  Lubna, qui fréquente régulièrement la mosquée, n'a pour sa part pas subi ce genre de violences, mais cela ne l'empêche pas de vivre dans la peur. « Je vis dans un quartier musulman, donc je ne me sens pas rejetée ou mise à l'écart. Mais si je devais sortir de ce quartier, je ne me sentirais pas en sécurité, affirme-t-elle, et je me sentirais en danger parce qu'après ce qui s'est passé en décembre, tout le monde accuse les musulmans. »  À lire aussiAustralie: au moins 16 morts dans une fusillade visant la communauté juive à Sydney, dont un assaillant Un racisme ancré historiquement Ce sentiment, partagé par la communauté musulmane, se traduit également dans les intentions de vote. Un récent sondage crédite ainsi One Nation de 26 % des voix, un niveau encore jamais atteint par ce parti d'extrême droite, qui, depuis trente ans, dénonce l'immigration non européenne.  Plus inquiétant encore, des groupuscules néo-nazis gagnent eux aussi en popularité. « Ils ont probablement doublé leur nombre en 2025 et pour eux, Bondi, c'était comme un trophée, analyse Kaz Ross, qui étudie depuis des années l'activité de ces groupes en ligne. Parce que leur argument, c'est de dire que ce massacre n'aurait pas eu lieu s'il n'y avait pas eu de juifs et de musulmans. Nous devons réintégrer tous ceux en Australie qui ne sont pas des Blancs d'ascendance européenne. »  Face à ce danger et suite à l'attentat de Bondi, le gouvernement a durci ses lois réprimant les discours de haine, ce qui a entraîné la dissolution du plus connu des groupes néo-nazis, le Réseau national socialiste.  Reste que pour Jordan McSwiney, spécialiste de l'extrême droite, le gouvernement pourrait mieux faire pour combattre le racisme : « On ne peut pas combattre efficacement le racisme en isolant une forme particulière de racisme, comme l'antisémitisme ou l'islamophobie, défend-il. Elles font partie d'une forme plus large de racisme et de suprématisme blanc qu'il faut absolument combattre. » De fait, la forme la plus négligée de racisme est aussi la plus ancienne, c'est le racisme qui cible les Aborigènes. Le 26 janvier dernier, à Perth, un homme a jeté une bombe artisanale en plein milieu d'un rassemblement aborigène, qui n'a heureusement pas explosé. Animé par des idées racistes, il a été inculpé pour terrorisme.  À lire aussiAustralie: les Aborigènes victimes d'un «génocide», l'État du Victoria face à son histoire

Research Identifies Link to Oral Cancer Progression, Associated Pain, and Specific Calcium ChannelBy Today's RDH ResearchOriginal article published on Today's RDH: https://www.todaysrdh.com/research-identifies-link-to-oral-cancer-progression-associated-pain-and-specific-calcium/Need CE? Start earning CE credits today at ⁠https://rdh.tv/ce⁠ Get daily dental hygiene articles at ⁠https://www.todaysrdh.com⁠ Follow Today's RDH on Facebook: ⁠https://www.facebook.com/TodaysRDH/⁠Follow Kara RDH on Facebook: ⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠Follow Kara RDH on Instagram: ⁠https://www.instagram.com/kara_rdh/⁠

In episode 310 of the podcast, we're joined by Daryl Taberski (vocals) of Snapcase.We dig into the 90s Buffalo scene, the formation of the band, signing with Victory Records, touring in the 90s, records (Progression, Designs, etc), the changing musical landscape over the years, what's next for the band, and everything in between. This is a classic past to present Podioslave special. Shouts to Daryl for being an all-time guest of the pod.Keep an eye out out for the upcoming Snapcase documentary (IG: @snapcaselegacy)Follow Snapcase on IG: @snapcasebandPhoto Credit: Greg Flack (IG: @xgregflackx)Podcast theme performed by Trawl. Follow them here:WebIG/X/TikTok: @trawlbandWe'd love for everyone to hear this episode! Support the Podioslave family by rating, subscribing, sharing, storying, tweeting, etc — you get the vibe. Peace, love, and PodioslaveCheck us out here:WebIG/Threads/X/TikTok: @PodioslaveYoutubeEmail: Podioslavepodcast@gmail.com

Does nutrition matter when you are facing prostate cancer? In this episode, Dr. Stephen Petteruti lays out a practical, data-driven framework for prostate cancer nutrition, cancer progression, metabolic health, PSA management, and longevity medicine. Portion control, feeding timing, insulin sensitivity, hemoglobin A1C, triglycerides, and visceral fat all matter. He explains why structured eating patterns, net carbohydrate awareness, and metabolic control often outweigh trendy diet labels.Dr. Stephen also addresses high-risk dietary exposures that many overlook: processed meats and nitrites, sodium benzoate, artificial sweeteners and weight gain signals, petroleum-based food dyes, and chronic high-sugar intake in insulin-resistant individuals.Instead of extreme restriction, he advocates strategic elimination of the biggest carcinogenic inputs while preserving quality of life.If you care about longevity, cancer prevention, and metabolic optimization, spend time with this episode of Best Diet for Prostate Cancer | What Actually Matters for Cancer Progression.Enjoy the podcast? Subscribe and leave a 5-star review.Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice. His approach prioritizes preserving function, strength, and quality of life while helping patients make clear, informed decisions beyond reactive, fear-driven care.Learn more: https://www.drstephenpetteruti.com/Learn more: https://www.intellectualmedicine.com/Connect with Dr. Petteruti on:⁠Instagram: ⁠https://www.instagram.com/dr.stephenpetteruti/⁠Facebook: ⁠https://www.facebook.com/dr.stephenpetteruti⁠Subscribe to Intellectual Medicine on:Apple Podcast: https://tinyurl.com/DrPetterutiApplePodcastSpotify: https://tinyurl.com/DrPetterutiSpotifyPodcastDisclaimer:The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, "Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial," by Harter et al. TRANSCRIPT Melis Canturk: Hello, and welcome to the JCO Article Insight. I'm your host, Melis Canturk, and today we will be discussing the JCO article, "Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial." While integrating immune checkpoint inhibitors has revolutionized the treatment of various gynecologic cancers, these agents have historically shown limited single agent activity in ovarian cancer. Despite a strong biological rationale for combining immunotherapy with chemotherapy and bevacizumab to enhance T-cell infiltration and normalized tumor vasculature, several phase III trials have failed to demonstrate a significant survival benefit in this setting. The AGO-OVAR 2.29/ENGOT-ov34 trial was launched to definitely evaluate whether adding the PD-L1 inhibitor atezolizumab to this combination could improve long-term outcomes for patients experiencing early relapse. This international, double-blind, randomized phase III trial enrolled 574 patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Eligible participants had to be in their first or second relapse within 6 months of completing platinum therapy or in their third relapse regardless of the treatment-free interval. All patients received bevacizumab and an investigator selected chemotherapy backbone, either paclitaxel or doxorubicin. They were randomly assigned to receive either 840 mg of atezolizumab or a placebo every 2 weeks until disease progression or for a maximum of 2 years. The study population was an all-comer group, though patients were stratified by their PD-L1 status, previous bevacizumab use, and the number of prior treatment lines. The trial did not meet its primary end points, as the addition of atezolizumab failed to significantly improve overall survival or progression-free survival in the intention-to-treat population. For the primary end point of overall survival, the median was 14.2 months with atezolizumab compared to 13 months with the placebo. Progression-free survival was similarly insignificant, with a median of 6.4 months in the experimental arm versus 6.7 months in the control arm. Furthermore, the objective response rates were nearly identical between the groups, recorded at 40% for atezolizumab and 44% for the placebo. Interestingly, exploratory subgroup analyses revealed potential signals of benefit in specific populations, even though the overall trial was negative. Patients who had been previously treated with bevacizumab appeared to derive a greater benefit from the addition of atezolizumab than those who were bevacizumab-naïve. Additionally, outcomes seemed more favorable for patients receiving a paclitaxel chemotherapy backbone compared to those receiving doxorubicin. However, PD-L1 status did not appear to be a predictive marker for success, as hazard ratios for survival were similar regardless of whether the tumor was PD-L1 positive or negative. The safety profile of the triple combination was consistent with the known toxicities of the individual drugs. Grade 3 or higher adverse events occurred in 73% of the atezolizumab group and 70% of the placebo group. While the experimental arm saw higher incidences of immune-mediated events, such as thyroid-related issues, these were generally manageable. Serious adverse events were more frequent in the atezolizumab arm than in the placebo arm, but discontinuation rates due to toxicity were relatively low and comparable between the two groups. In conclusion, the AGO-OVAR 2.29 trial confirms that adding atezolizumab to bevacizumab and nonplatinum chemotherapy does not provide a statistically significant survival advantage for patients who receive nonplatinum chemotherapy for recurrent ovarian cancer. This study contributes to the growing body of evidence showing that immune checkpoint inhibitors have yet to find a definitive role in the standard treatment of recurrent ovarian cancer. Future research will likely focus on more sophisticated molecular stratification and the use of novel agents, such as bispecific antibodies, to overcome the challenging tumor microenvironment of low-grade serous ovarian cancer. Thank you for tuning into JCO Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Termines-tu parfois ta journée avec un sentiment d'inachevé, même après avoir été occupé du matin au soir? Tu regardes ta liste… Et tu vois surtout ce qui reste à faire. C'est décourageant.Dans cet épisode, on parle de la “to-do list inversée” : écrire ce qu'on a accompli plutôt que ce qu'il reste à faire.Est-ce une bonne idée? Est-ce stratégique? Ou est-ce une façon de se donner bonne conscience?On explore l'équilibre entre :Une vraie liste de tâches stratégique qui fait avancer tes priorités Une liste d'accomplissements qui nourrit ta motivation et ta confianceParce qu'une bonne planification te donne une direction. Mais reconnaître ton progrès te donne du momentum.Si tu veux finir tes journées avec un sentiment d'accomplissement, cet épisode est pour toi.LIENS ET RESSOURCES :

WBZ NewsRadio’s Kendall Buhl reports.See omnystudio.com/listener for privacy information.

Sale announcement: 25% OFF ALL TTM PROGRAMS — sale ends Feb. 22. If you're serious about improving performance, now is the time to start. Today's Q&A topics:03:18 - Subs for sled push work?06:50 - Min effective dose of conditioning when trying to bulk10:59 - Should you stay in SFAS prep mode year-round?15:24 - Best times of year to go to selection19:33 - Tips for sleep health when working overnight22:01 - Skipping test/deload weeks pre-SFAS24:54 - Prepping for the Norwegian march 25:40 - Is it effective to train biceps + triceps every day for bigger arms?29:10 - Considerations for training late in the evening 34:29 - Sub for 400 meter repeats if no access to a track36:29 - Things to consider with sand beach runs38:19 - How to progress ruck weight and time41:26 - How to maintain motivation for the Q when injured—Questions? Look for bi-weekly Q&A on my stories. I'll answer your questions on IG and here on the podcast.—New Selection Prep Program: Ruck | Run | Lift New Hybrid Program: Jacked Gazelle 3.0Ebook: SOF Selection Recovery & Nutrition Guide—TrainHeroic Team Subscription: T-850 Rebuilt (try a week for free!)—PDF programs2 & 5 Mile Run Program - run improvement program w/ strength workKickstart- beginner/garage gym friendlyTime Crunch- Workouts for those short on timeHypertrophy- intermediate/advancedJacked Gazelle- Hybrid athleteJacked Gazelle 2.0 - Hybrid athleteSFAS Prep- Special forces train-upRuck | Run | Lift - Selection Prep—Spoken Supplements: Code terminator_trainingCwench supplements: Code terminator_training—Let's connect:Newsletter Sign UpIG: terminator_trainingYoutube: Terminator Training Methodwebsite: terminatortraining.comSubstack

Le sujet fort de l'actualité foot du jour vu par Jérôme Rothen et la Dream Team.

JCO PO author Dr. Foldi at UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine shares insights into the JCO PO article, "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast." Host Dr. Rafeh Naqash and Dr. Foldi discuss how serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are thrilled to be joined by Dr. Julia Foldi, Assistant Professor of Medicine in the Division of Hematology-Oncology at University of Pittsburgh School of Medicine and the Magee-Womens Hospital of the UPMC. She is also the lead and corresponding author of the JCO Precision Oncology article entitled "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients with Metastatic Invasive Lobular Carcinoma of the Breast." At the time of this recording, our guest's disclosures will be linked in the transcript. Julia, welcome to our podcast, and thank you for joining us today. Dr. Julia Foldi: Thank you so much for having me. It is a pleasure. Dr. Rafeh Naqash: Again, your manuscript and project address a few interesting things, so we will start with the basics, since we have a broad audience that comprises trainees, community oncologists, and obviously precision medicine experts as well. So, let us start with invasive lobular breast carcinoma. I have been out of fellowship for several years now, and I do not know much about invasive lobular carcinoma. Could you tell us what it is, what some of the genomic characteristics are, why it is different, and why it is important to have a different way to understand disease biology and track disease status with this type of breast cancer? Dr. Julia Foldi: Yes, thank you for that question. It is really important to frame this study. So, lobular breast cancers, which we shorten to ILC, are the second most common histologic subtype of breast cancer after ductal breast cancers. ILC makes up about 10 to 15 percent of all breast cancers, so it is relatively rare, but in the big scheme of things, because breast cancer is so common, this represents actually over 40,000 new diagnoses a year in the US of lobular breast cancers. What is unique about ILC is it is characterized by loss of an adhesion molecule, E-cadherin. It is encoded by the CDH1 gene. What it does is these tumors tend to form discohesive, single-file patterns and infiltrate into the tumor stroma, as opposed to ductal cancers, which generally form more cohesive masses. As we generally explain to patients, ductal cancers tend to form lumps, while lobular cancers often are not palpable because they infiltrate into the stroma. This creates several challenges, particularly when it comes to imaging. In the diagnostic setting, we know that mammograms and ultrasounds have less sensitivity to detect lobular versus ductal breast cancer. When it comes to the metastatic setting, conventional imaging techniques like CT scans have less sensitivity to detect lobular lesions often. One other unique characteristic of ILC is that these tumors tend to have lower proliferation rates. Because our glucose-based PET scans depend on glucose uptake of proliferating cells, often these tumors also are not avid on conventional FDG-PET scans. It is a challenge for us to monitor these patients as they go through treatment. If you think about the metastatic setting, we start a new treatment, we image people every three to four cycles, about every three months, and we combine the imaging results with clinical assessment and tumor markers to decide if the treatment is working. But if your imaging is not reliable, sometimes even at diagnosis, to really detect these tumors, then really, how are we following these patients? This is really the unique challenge in the metastatic setting in patients with lobular breast cancer: we cannot rely on the imaging to tell if patients are responding to treatment. This is where liquid biopsies are really, really important, and as the field is growing up and we have better and better technologies, lobular breast cancer is going to be a field where they are going to play an important role. Dr. Rafeh Naqash: Thank you for that easy-to-understand background. The second aspect that I would like to have some context on, to help the audience understand why you did what you did, is ctDNA, tumor informed and non-informed. Could you tell us what these subtypes of liquid biopsies are and why you chose a tumor informed assay for your study? Dr. Julia Foldi: Yes, it is really important to understand these differences. As you mentioned, there are two main platforms for liquid biopsy assays, circulating tumor DNA assays. I think what is more commonly used in the metastatic setting are non-tumor informed assays, or agnostic assays. These are generally next-generation sequencing-based assays that a lot of companies offer, like Guardant, Tempus, Caris, and FoundationOne. These do not require tumor tissue; they just require a blood sample, a plasma sample, essentially. The next-generation sequencing is done on cell-free DNA that is extracted from the plasma, and it is looking for any cell-free DNA and essentially, figuring out what part of the cell-free DNA comes from the tumor is done through a bioinformatics approach. Most of these assays are panel tests for cancer-associated mutations that we know either have therapeutic significance or biologic significance. So, the results we receive from these tests generally read out specific mutations in oncogenic genes, or sometimes things like fusions where we have specific targeted drugs. Some of the newer assays can also read out tumor fraction; for example, the newest generation Guardant assay that is methylation-based, they can also quantify tumor fraction. But the disadvantage of the tumor agnostic approach is that it is a little bit less sensitive. Opposed to that, we have our tumor informed tests, and these require tumor tissue. Essentially, the tumor is sequenced; this can either be whole exome or whole genome sequencing. The newer generation assays are now using whole genome sequencing of the tumor tissue, and a personalized, patient-specific panel of alterations is essentially barcoded on that tumor tissue. This can be either structural variants or it can be mutations, but generally, these are not driver mutations, but sort of things that are present in the tumor tissue that tend to stay unchanged over time. For each particular patient, a personalized assay, if you want to call it a fingerprint or barcode, is created, and then that is what then is used to test the plasma sample. Essentially, you are looking for that specific cancer in the blood, that barcode or fingerprint in the blood. Because of this, this is a much more sensitive way of looking for ctDNA, and obviously, this detects only that particular tumor that was sequenced originally. So, it is much more sensitive and specific to that tumor that was sequenced. You can argue for both approaches in different settings. We use them in different settings because they give us different information. The tumor agnostic approach gives us mutations, which can be used to determine what the next best therapy to use is, while the tumor informed assay is more sensitive, but it is not going to give us information on therapeutic targets. However, it is quantified, and we can follow it over time to see how it changes. We think that it is going to tell us how patients respond to treatment because we see our circulating tumor DNA levels rise and fall as the cancer burden increases or decreases. We decided to use the tumor informed approach in this particular study because we were really interested in how to determine if patients are having response to treatment versus if they are going to progress on their treatment, more so than looking for specific mutations. Dr. Rafeh Naqash: When you think about these tumor informed assays and you think about barcoding the mutations on the original tumor that you try to track or follow in subsequent blood samples, plasma samples, in your experience, if you have done it in non-lobular cancers, do you think shedding from the tumor has something to do with what you capture or how much you capture? Dr. Julia Foldi: Absolutely. I think there are multiple factors that go into whether someone has detectable ctDNA or not, and that has to do with the type of cancer, the location, right, where is the metastatic site? This is something that we do not fully understand yet: what are tumors that shed more versus not? There is also clearance of ctDNA, and so how fast that clearance occurs is also something that will affect what you can detect in the blood. ctDNA is very short-lived, only has a half-life of hours, and so you can imagine that if there is little shedding and a lot of excretion, then you are not going to be detecting a lot of it. In general, in the metastatic setting, we see that we can detect ctDNA in a lot of cases, especially when patients are progressing on treatment, because we imagine their tumor burden is higher at that point. Even with the non-tumor informed assays, we detect a lot of ctDNA. Part of this study was to actually assess: what is the proportion of patients where we can have this information? Because if we are only going to be able to detect ctDNA in less than 50 percent of patients, then it is not going to be a useful method to follow them with. Because this field is new and we have not been using a lot of tumor informed assays in the metastatic setting, we did not really know what to expect when we set out to look at this. We did not know what was going to be the baseline detection rate in this patient population, so that was one of the first things that we wanted to answer. Dr. Rafeh Naqash: Excellent. Now going to this manuscript in particular, what was the research question, what was the patient population, and what was the strategy that you used to investigate some of these questions? Dr. Julia Foldi: So, we partnered with Natera, and the reason was that their Signatera tumor-informed assay was the first personalized, tumor-informed, really an MRD assay, minimal residual disease detection assay. It has been around the longest and has been pretty widely used commercially already, even though some of our data is still lacking. but we know that people are using this in the real world. We wanted to gather some real-world data specifically in lobular patients. So, we asked Natera to look at their database of commercial Signatera testing and look for patients with stage 4 lobular breast cancer. The information all comes from the submitting physicians sending in pathologic reports and clinical notes, and so they have that information from the requisitions essentially that are sent in by the ordering physician. We found 66 patients who were on first-line or close to first-line endocrine-based therapies for their metastatic lobular breast cancer and had serial collections of Signatera tests. The way we defined baseline was that the first Signatera had to be sent within three months of starting treatment. So, it is not truly baseline, but again, this is a limitation of looking at real-world data is that you are not always going to get the best time point that you need. We had over 350 samples from those 66 patients, again longitudinal ctDNA samples, and our first question was what is the baseline detection rate using this tumor informed assay? Then, most importantly, what is the concordance between changes in ctDNA and clinical response to treatment? That is defined by essentially radiologic response to treatment. Dr. Rafeh Naqash: Interesting. So, what were some of your observations in terms of ctDNA dynamics, whether baseline levels made a difference, whether subsequent levels at different time points made a difference, or subsequent levels at, let us say, cycle three made a difference? Were there any specific trends that you saw? Dr. Julia Foldi: So, first, at baseline, 95 percent of patients had detectable ctDNA, which is, I think, a really important data point because it tells us that this can be a really useful test. If we can detect it in almost all patients before they start treatment, we are going to be able to follow this longitudinally. And again, these were not true baseline samples. So, I think if we look really at baseline before starting treatment, almost all patients will have detectable ctDNA in the metastatic setting. The second important thing we saw was that disease progression correlated very well with increase in ctDNA. So, in most patients who had disease progression by imaging, we saw increase in ctDNA. Conversely, in most patients who had clinical benefit from their treatment, so they had a response or stable disease, we saw decrease in ctDNA levels. It seems that what we call molecular response based on ctDNA is tracking very nicely along with the radiographic response. So, those were really the two main observations. Again, this is a small cohort, limited by its real-world nature and the time points that ctDNA assay was sent was obviously not mandated. This is a real-world data set, and so we could not really look at specific time points like you asked about, let us say, cycle three of therapy, right? We did not have all of the right time points for all of the patients. But what we were able to do was to graph out some specific patient scenarios to illustrate how changes in ctDNA correlate with imaging response. I can talk a little bit about that. Dr. Rafeh Naqash: That was going to be my question. Did you see patients who had serial monitoring using the tumor informed ctDNA assay where the assay became positive a few months before the imaging? Did you have any of those kinds of observations? Dr. Julia Foldi: Yes, so I think this is where the field is going: are we able to use this technology to maybe detect progression before it becomes clinically apparent? Of course, there are lots of questions about: does that really matter? But it seems like, based on some of the patient scenarios that we present in the paper, that this testing can do that. So, we had a specific scenario, and this is illustrated in a figure in the paper, really showing the treatment as well as the changes in ctDNA, tumor markers, and also radiographic response. So, this particular patient was on first-line endocrine therapy and CDK4/6 inhibitor with palbociclib. Initially, she had a low-level detectable ctDNA. It became undetectable during treatment, and the patient had a couple of serial ctDNA assays that were negative, so undetectable. And then we started, after about seven months on this combination therapy, the ctDNA levels started rising. She actually had three serial ctDNA assays with increasing level of ctDNA before she even had any imaging tests. And then around the time that the ctDNA peaked, this patient had radiographic evidence of progression. There was also an NGS-based assay sent to look for specific mutations at that point. The patient was found to have an ESR1 mutation, which is very common in this patient population. She was switched to a novel oral SERD, elacestrant, and the ctDNA fell again to undetectable within the first couple months of being on elacestrant. And then a very similar thing happened: while she was on this second-line therapy, she had three serial negative ctDNA assays, and then the fourth one was positive. This was two months before the patient had a scan that showed progression again. Dr. Rafeh Naqash: And Julia, like you mentioned, this is a small sample size, limited number of patients, in this case, one patient case scenario, but provides insights into other important aspects around escalation or de-escalation of therapy where perhaps ctDNA could be used as an integral biomarker rather than an exploratory biomarker. What are some of your thoughts around that and how is the breast cancer space? I know like in GI and bladder cancer, there has been a significant uptrend in MRD assessments for therapeutic decision making. What is happening in the breast cancer space? Dr. Julia Foldi: So, super interesting. I think this is where a lot of our different fields are going. In the breast cancer space, so far, I have seen a lot of escalation attempts. It is not even necessarily in this particular setting where we are looking at dynamics of ctDNA, but in the breast cancer world, of course, we have a lot of data on resistance mutations. I mentioned ESR1 mutation in a particular patient in our study. ESR1 mutations are very common in patients with ER-positive breast cancer who are on long-term endocrine therapy, and ESR1 mutations confer resistance to aromatase inhibitors. So, that is an area that there has been a lot of interest in trying to detect ESR1 mutations earlier and switching therapy early. So, this was the basis of the SERENA-6 trial, which was presented last year at ASCO and created a lot of excitement. This was a trial where patients had non-tumor-informed NGS-based Guardant assay sent every three to six months while they were on first-line endocrine therapy with a CDK4/6 inhibitor. If they had an ESR1 mutation detected, they were randomized to either continue the same endocrine therapy or switch to an oral SERD. The trial showed that the population of patients who switched to the oral SERD did better in terms of progression-free survival than those who stayed on their original endocrine therapy. There are a lot of questions about how to use this in routine practice. Of course, it is not trivial to be sending a ctDNA assay every three to six months. The rate of detection of these mutations was relatively low in that study; again, the incidence increases in later lines of therapy. So, there are a lot of questions about whether we should be doing this in all of our first-line patients. The other question is, even the patients who stayed on their original endocrine therapy were able to stay on that for another nine months. So, there is this question of: are we switching patients too early to a new line of therapy by having this escalation approach? So, there are a lot of questions about this. As far as I know, at least in our practice, we are not using this approach just yet to escalate therapy. Time will tell how this all pans out. But I think what is even more interesting is the de-escalation question, and I think that is where tumor informed assays like Signatera and the data that our study generated can be applied. Actually, our plan is to generate some prospective data in the lobular breast cancer population, and I have an ongoing study to do that, to really be able to tease out the early ctDNA dynamics as patients first start on endocrine therapy. So, this is patients who are newly diagnosed, they are just starting on their first-line endocrine therapy, and measure, with sensitive assays, measure ctDNA dynamics in the first few months of therapy. In those patients who have a really robust response, that is where I think we can really think about de-escalation. In the patients whose ctDNA goes to undetectable after just a few weeks of therapy with just an endocrine agent, they might not even need a CDK4/6 inhibitor in their first-line treatment. So, that is an area where we are very interested in our group, and I know that other groups are looking at this too, to try to de-escalate therapy in patients who clear their ctDNA early on. Dr. Rafeh Naqash: Thank you so much. Well, lots of questions, but at the same time, progress comes through questions asked, and your project is one of those which is asking an interesting question in a rarer cancer and perhaps will lead to subsequent improvement in how we monitor these individuals and how we escalate or de-escalate therapy. Hopefully, we will get to see more of what you are working on in subsequent submissions to JCO Precision Oncology and perhaps talk more about it in a couple of years and see how the space and field is moving. Thanks again for sharing your insights. I do want to take one to two quick minutes talking about you as an investigator, Julia. If you could speak to your career pathway, your journey, the pathway to mentorship, the pathway to being a mentor, and how things have shaped for you in your personal professional growth. Dr. Julia Foldi: Sure, yeah, that is great. Thank you. So, I had a little bit of an unconventional path to clinical medicine. I actually thought I was going to be a basic scientist when I first started out. I got a PhD in Immunology right out of college and was studying not even anything cancer-related. I was studying macrophage signaling in inflammatory diseases, but I was in New York City. This was right around the time that the first checkpoint inhibitors were approved. Actually, some of my friends from my PhD program worked in Jim Allison's lab, who was the basic scientist responsible for ipilimumab. So, I got to kind of first-hand experience the excitement around bringing something from the lab into the clinic that actually changed really the course of oncology. And so, I got very excited about oncology and clinical medicine. So, I decided to kind of switch gears from there and I went back to medical school after finishing my PhD and got my MD at NYU. I knew I wanted to do oncology, so I did a research track residency and fellowship combined at Yale. I started working early on with the breast cancer team there. At the time, Lajos Pusztai was the head of translational research there at Yale, and I started working with him early in my residency and then through my fellowship. I worked on several trials with him, including a neoadjuvant checkpoint inhibitor trial in triple-negative breast cancer patients. During my last year in fellowship, I received a Conquer Cancer Young Investigator Award to study estrogen receptor heterogeneity using spatial transcriptomics in this subset of breast cancers that have intermediate estrogen receptor expression. From there, I joined the faculty at the University of Pittsburgh in 2022. So, I have been there about almost four years at this point. My interests really shifted slowly from triple-negative breast cancers towards ER-positive breast cancers. When I arrived in Pittsburgh, I started working very closely with some basic and translational researchers here who are very interested in estrogen signaling and mechanisms of resistance to endocrine therapy, and there is a large group here interested in lobular breast cancers. During my training, I was not super aware even that lobular breast cancer was a unique subtype of breast cancers, and that is, I think, changing a little bit. There is a lot more awareness in the breast cancer clinical and research community about ILC being a unique subtype, but it is not even really part of our training in fellowship, which we are trying to change. But I have become a lot more aware of this because of the research team here and through that, I have become really interested also on the clinical side. And so, we do have a Lobular Breast Cancer Research Center of Excellence here at the University of Pittsburgh and UPMC, and I am the leader on the clinical side. We have a really great team of basic and translational researchers looking at different aspects of lobular breast cancers, and some of the work that I am doing is related to this particular manuscript we discussed and the next steps, as I mentioned, a prospective study of early ctDNA dynamics in lobular patients. I also did some more clinical research work in collaboration with the NSABP looking at long-term outcomes of patients with lobular versus ductal breast cancers in some of their older trials. And so, that is, in a nutshell, a little bit about how I got here and how I became interested in ILC. Dr. Rafeh Naqash: Well, thank you for sharing those personal insights and personal journey. I am sure it will inspire other trainees, fellows, and perhaps junior faculty in trying to find their niche. The path, as you mentioned, is not always straight; it often tends to be convoluted. And then finding an area that you are interested in, taking things forward, and being persistent is often what matters. Dr. Julia Foldi: Thank you so much for having me. It was great. Dr. Rafeh Naqash: It was great chatting with you. And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

On episode 734 of 40+ Fitness Podcast, we dive into the world of hybrid athleticism with Alex Vieira, renowned coach, educator, and author of The Ultimate Hybrid Athlete: A Definitive Guide to Achieving Peak Athleticism Across All Disciplines. Hosted by Allan, this episode explores what it really means to be a "hybrid athlete"—balancing strength, endurance, and overall resilience no matter your age. Alex shares his journey from clinical research to coaching more than 1,000 athletes, and explains how anyone—regardless of body type or background—can train to be both strong and enduring. You'll learn about eliminating "junk volume" in your workouts, the true meaning of progressive overload, and how to periodize your training when you're balancing multiple athletic goals. Plus, Alex introduces the RAMP warm-up system, and offers practical strategies for staying healthy, fit, and mentally sharp well into your 40s and beyond. Time Stamps: 05:38 Embracing Growth Beyond Identity 07:21 Training with Intent 10:17 Progressive Overload Simplified 15:06 Hybrid Training and Progression 18:43 Steps to Optimize Workout Prep 22:56 70/30 Diet Planning Approach 23:52 Balance Life and Sharpen Mind https://completehumanperformance.com  

Fr. Dan Reehil uses today's first reading to explain the nature and progression of sin.Radio Maria is a 100% listener supported radio station. If this broadcast has touched your life, please consider donating at https://rmusa.civi-go.net/donateStream live episodes of Battle Ready with Fr. Dan Reehil at https://radiomaria.us/ at 9:00 am cst or tune in on radio in Louisiana (580 AM Alexandria, 1360 AM New Iberia, 89.7 FM Natchitoches, 91.1 FM Lake Charles) in Ohio (1600 AM Springfield, 88.7 FM Anna, 103.3 Enon/Dayton) in Mississippi (88.1 FM D'Iberville/Biloxi) in Florida (91.9 Hammocks/Miami) in Pennsylvania (88.1 FM Hollidaysburg/Altoona) in Texas (1250 AM Port Arthur) in Wisconsin (91.3 FM Peshtigo), 1280 AM Columbia, TN (98.9 FM Columbia, TN)Download the Radio Maria Play app to any smart device:Android: https://play.google.com/store/apps/details?id=com.radiomaria.v3&hl=en_US&gl=US&pli=1iOS: https://apps.apple.com/us/app/radio-maria-play/id848153139 

Sean tells Don and Sam about getting sober at 15, never having had a legal drink. Sean's early exposure to AA was through a rehab. He remembers going to a meeting which was just the leader and the other folks from his rehab. He was impressed when the leader said he was serving in the role because he didn't want to drink. There's a History Snippet with Mily, and Martina shares her love for Grapevine.While we provide the podcast at no charge, we do have expenses. Grapevine is the only AA entity that does not accept direct contributions, so to support the AA Grapevine Podcast, please subscribe to Grapevine Magazine in print, online, or on the Grapevine app. You can also provide a subscription to someone in need through our "Carry the Message" program or purchase books or other items at aagrapevine.org/storeYou can email us at podcast@aagrapevine.org. To record an Ask-It-Basket question or a recovery-related joke, call 212-870-3418 or email a voice recording to podcast@aagrapevine.org

Dr. Greg Cooper and Dr. David G. Coughlin discuss the role of αSyn-SAAs in diagnosing DBL and their relationship with Alzheimer's disease biomarkers.  Show citation: Coughlin DG, Jain L, Khrestian M, et al. CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression. Neurology. 2025;105(12):e214346. doi:10.1212/WNL.0000000000214346 Show transcript:  Dr. Greg Cooper: Hi, this is Dr. Greg Cooper. I just finished interviewing Dr. David Coughlin for this week's Neurology Podcast. For today's Neurology Minute, I'm hoping you can tell us the main points of your paper. Dr. David Coughlin: The main points of this paper in my mind is that α-Synuclein seed amplification assays from cerebrospinal fluid samples is useful in confirming the presence of synuclein pathology in people with clinically suspected dementia with Lewy bodies. But also that, for people who have synuclein positivity, that the presence of Alzheimer's disease mixed pathology is associated with a worse cognitive progression over time. Dr. Greg Cooper: Thank you Dr. Coughlin, for that summary and for all of your work on this topic. Please check out this week's podcast to hear the full interview and read the full article published in Neurology, CSF α-Synuclein Seed Amplification Assays and Alzheimer's Disease Biomarkers in Dementia with Lewy Bodies. Thank you.

IgA nephropathy remains the most common immune-mediated glomerular disease worldwide — and up to 50% of patients may progress to kidney failure within a decade.

Vortex Edge instructor/RSO Chris Urrutia, a Marine vet, ex-SWAT sniper, SPECtrain founder, unpacks razor-sharp training at Vortex Optics HQ with us today in reflection of a recent trip we had out to the Vortex HQ and Edge facility in Wisconsin. Today, Chris and I will discuss pistol fundamentals, training discipline, how he measures progress, and, of course, what some of his current favorite pieces of gear are in 2026. Vortex Edge Vortex Optics Vortex Optics Facebook Vortex Optics Instagram Vortex Edge YouTube  

In this detailed conversation, Alex Harvey discusses his recent impressive half marathon in Japan, the skepticism around his progression, and his transparent use of Strava to share his full training. Alex breaks down his early marathon times and steady improvement through consistent training. He covers marathon challenges (fueling and getting intensity right), how business and family life fits around training, and his aspirations heading into Tokyo Marathon. He also shares why racing without a strict time goal can be valuable, plus how context-specific training has helped him progress. We also get into his preference for training alone, keeping training efficient, and his approach to diet - along with why he largely avoids strength training and cross training. Follow Alex Instagram: https://www.instagram.com/alexxharvey/ Strava: https://www.strava.com/athletes/46089368/ Work With / Follow Matt Coaching: https://www.sweatelitecoaching.com/coaching-2026 Shareholders Club / Private Feed: https://www.sweatelite.co/shareholders Instagram: https://www.instagram.com/mattinglisfox/ Strava: https://www.strava.com/athletes/6248359 Contact: matt@sweatelite.co Topics 00:00 Introduction and Recent Achievements 00:10 Addressing Skepticism and Progression 02:42 Early Running Experiences 03:51 Transition to Serious Training 05:05 High School and Early Twenties 07:35 Inspiration to Start Running 09:38 Recent Race Highlights 12:59 Training Philosophy and Volume 17:48 Training Alone and Flexibility 19:42 Speed Work and Coaching 24:28 Long Runs and Marathon Preparation 25:03 Training in the Heat: Adapting to Queensland's Climate 26:02 Key Training Sessions: Building Endurance and Speed 27:09 Mental Strategies for Pacing and Performance 30:21 Fueling Challenges and Solutions 33:34 Balancing Life: Business, Family, and Running 38:28 Speed and Distance: Exploring Potential and Preferences 41:59 Diet and Weight Management for Optimal Performance 44:45 Cross Training and Strength Training Insights 47:16 Final Thoughts and Where to Follow

Improve your foiling skills in paradise! Join us in Montanita Ecuador May 23-30, 2026 for a foil drive / tow / prone foil camp with Ecuador Foil, KT Foiling & Julia Castro. Learn MoreOn this episode, Gaetan (founder of Colombia eFoil) and Justin Chait (experienced eFoil coach and instructor) join us to talk about the building and running one of the premier e-foiling destinations in the Caribbean: a multi-location flight school and immersive retreat experience on the stunning Isla Barú peninsula near Cartagena, Colombia.They share how Gaetan turned his passion for water sports—and his first e-foil flight (with Justin as his original instructor)—into a thriving business launched exactly two years ago, now operating out of luxury resorts including Aura Hotel Barú (the flagship spot with beachfront access), Sofitel Barú, and Hotel Las Islas.Episode Highlights:- The paradise-like conditions that make Barú an ideal e-foiling hub: flat, protected bay waters with mangroves, kilometers of glassy riding, warm 30°C+ water, consistent year-round weather (rare closures), and easy access to open ocean and nearby islands like Islas del Rosario for long-distance adventures- How the operation works: three fully equipped bases with rescue boats, on-site charging, instructor-led boat coaching for safety and video feedback, premium service (boards prepped and rinsed for you), and the ability to ride from sunrise to sunset in board shorts- Justin's coaching philosophy: breaking down fundamentals for riders of all levels, re-teaching body position and throttle control to build safer, more efficient technique that reduces fatigue and extends battery life—turning intermediates into advanced riders and helping beginners fly in days- The famous 6-day eFoil retreats: beginner-friendly versions with open-sea crossings and island lunches by day 3; advanced/pro camps featuring daily drone video analysis, lap-time courses, wave riding, racing drills, 4–5 hours of riding per day, and group energy that pushes everyone's limits- Progression stories: students winning divisions at major events like Dubai after training there, couples where non-riding partners end up hooked, riders from 20 to 69 years old shredding (including 69-year-old wing-breeching legends), and a high return rate (~50%) of participants who come back for multiple retreats- Gear & practical details: primarily using Fliteboard (as official distributor in Colombia), options to bring your own setup or rent, testing different wings/shims during retreats, what to pack (sunscreen, rash guard, hat, sunglasses—no wetsuit needed), and full all-inclusive logistics from airport pickup to excursions, diving, gourmet meals (fresh snook, octopus, tropical fruits), and epic group dinners/parties- Why Colombia (especially Cartagena/Barú) is a game-changer for e-foiling: safe, tourist-friendly area with world-class resorts, incredible value, crystal-clear waters, wildlife, and a welcoming vibe that builds lasting rider friendships and communitiesIf you're dreaming of learning e-foiling in perfect warm flat water, accelerating your skills with world-class coaching, chasing long-distance island runs, or simply enjoying a luxury Caribbean foiling vacation—this conversation is loaded with inspiration, real-world insights, and pure stoke.Check out Colombia eFoil at colombiaefoil.com (retreat details at www.colombiaefoil.com/efoil-retreat), reach them via WhatsApp (+57 304 315 1220), email (booking@colombiaefoil.com), or Instagram @colombia_efoil. They're also highly rated on TripAdvisor and Google with hundreds of 5-star reviews.Listen now and start planning your own e-foil escape to Cartagena & Barú!

On this episode, Gaetan (founder of Colombia eFoil) and Justin Chait (experienced eFoil coach and instructor) join us to talk about the building and running one of the premier e-foiling destinations in the Caribbean: a multi-location flight school and immersive retreat experience on the stunning Isla Barú peninsula near Cartagena, Colombia.They share how Gaetan turned his passion for water sports—and his first e-foil flight (with Justin as his original instructor)—into a thriving business launched exactly two years ago, now operating out of luxury resorts including Aura Hotel Barú (the flagship spot with beachfront access), Sofitel Barú, and Hotel Las Islas.Episode Highlights:- The paradise-like conditions that make Barú an ideal e-foiling hub: flat, protected bay waters with mangroves, kilometers of glassy riding, warm 30°C+ water, consistent year-round weather (rare closures), and easy access to open ocean and nearby islands like Islas del Rosario for long-distance adventures- How the operation works: three fully equipped bases with rescue boats, on-site charging, instructor-led boat coaching for safety and video feedback, premium service (boards prepped and rinsed for you), and the ability to ride from sunrise to sunset in board shorts- Justin's coaching philosophy: breaking down fundamentals for riders of all levels, re-teaching body position and throttle control to build safer, more efficient technique that reduces fatigue and extends battery life—turning intermediates into advanced riders and helping beginners fly in days- The famous 6-day eFoil retreats: beginner-friendly versions with open-sea crossings and island lunches by day 3; advanced/pro camps featuring daily drone video analysis, lap-time courses, wave riding, racing drills, 4–5 hours of riding per day, and group energy that pushes everyone's limits- Progression stories: students winning divisions at major events like Dubai after training there, couples where non-riding partners end up hooked, riders from 20 to 69 years old shredding (including 69-year-old wing-breeching legends), and a high return rate (~50%) of participants who come back for multiple retreats- Gear & practical details: primarily using Fliteboard (as official distributor in Colombia), options to bring your own setup or rent, testing different wings/shims during retreats, what to pack (sunscreen, rash guard, hat, sunglasses—no wetsuit needed), and full all-inclusive logistics from airport pickup to excursions, diving, gourmet meals (fresh snook, octopus, tropical fruits), and epic group dinners/parties- Why Colombia (especially Cartagena/Barú) is a game-changer for e-foiling: safe, tourist-friendly area with world-class resorts, incredible value, crystal-clear waters, wildlife, and a welcoming vibe that builds lasting rider friendships and communitiesIf you're dreaming of learning e-foiling in perfect warm flat water, accelerating your skills with world-class coaching, chasing long-distance island runs, or simply enjoying a luxury Caribbean foiling vacation—this conversation is loaded with inspiration, real-world insights, and pure stoke.Check out Colombia eFoil at colombiaefoil.com (retreat details at www.colombiaefoil.com/efoil-retreat), reach them via WhatsApp (+57 304 315 1220), email (booking@colombiaefoil.com), or Instagram @colombia_efoil. They're also highly rated on TripAdvisor and Google with hundreds of 5-star reviews.Listen now and start planning your own e-foil escape to Cartagena & Barú!

Exercise can ease Parkinson's symptoms — but can it also slow the disease itself?In this Being Patient Live Talk, Northwestern University researcher Daniel Corcos, PhD breaks down the science behind high-intensity aerobic exercise and why his team is putting it to the test in a major Phase 3 clinical trial (SPARX3). SPARX3 is designed to examine whether exercise intensity can influence Parkinson's progression, especially for people who are newly diagnosed and not yet taking Parkinson's medication.Corcos, a professor in Northwestern's Department of Physical Therapy and Human Movement Sciences, shares what research has already taught us about exercise and Parkinson's — and what we still need to prove. He also lays out a practical, four-part “exercise prescription” you can use as a framework:✅ Aerobic training✅ Resistance/strength work✅ Flexibility✅ Balance + neuromotor trainingYou'll also learn how SPARX3 will follow 370 participants over two years, comparing moderate- vs. high-intensity treadmill training and tracking changes in symptoms and brain imaging to explore whether higher intensity is linked to slower progression.Hosted by: Deborah Kan, Founder of Being Patient--- Subscribe for more Live Talks and brain health reporting:https://www.beingpatient.com/Follow Being Patient:Twitter/X:   / being_patient  Instagram:   / beingpatientvoices  Facebook:   / beingpatientalzheimers  LinkedIn:   / being-patient  Watch more Live Talks:https://beingpatient.com/live-talks/Being Patient is an editorially independent journalism outlet covering brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series, founder and former Wall Street Journal editor Deborah Kan interviews brain health experts and people living with dementia.#parkinsonsdisease #Exercise #SPARX3 #BrainHealth #Neurology #ParkinsonsResearch #Fitness #MovementDisorder #BeingPatient

Send a textWelcome Back to The Beyond Condition PodcastJoin me for a solo episode where I share an important message with our community: progress is achievable for everyone, but understanding the toll it takes on you is crucial.‘Is Obsession Holding You Back From More Progression?'Each of us has our own unique journey, complete with past experiences and future aspirations. Several factors might influence your perception of how ‘obsessed' we should be to make progress. My aim is to provide insights that will enhance your understanding of the pillars of progression.Topics Discussed:Monitoring ProgressionSelf-AwarenessUnderstanding Your Own Belief SystemCommunication with Your CoachI hope you enjoy this episode, and as always, thank you for your unwavering support.S xWatch it here: https://youtu.be/EdcHClGJN7AFind Sarah on Instagram: @sarahparker_bb THE ULTIMATE SHOW DAY GUIDE E-BOOK: Purchase here Beyond Condition Coaching Application: Click here

This episode features Rich Summers(IG: @rich_somers) a real estate investor managing $90 million in assets and several boutique hotels, and Michael Sartain, a personal branding and marketing expert. The dialogue covers multiple topics including personal branding, social media strategies, sales tactics, dating dynamics, mindset, business scaling, and societal observations. 00:00 - Intro 01:14 - Victim Mentality vs. Ownership 02:40 - Strategies for Social Media Viral Growth 05:34 - The Value of Long Form Content 07:55 - Building a Repeatable Content System 09:34 - Building a Personal Brand for Status 11:26 - Tactics for Progression in Dating 13:39 - Leveraging Team Dynamics for Trust 15:38 - Time Management and Meeting Systems 18:29 - Business Lessons from Industry Leaders 21:08 - Scaling Brands with Paid Advertising 22:59 - Monetizing Podcasts and Yacht Workshops 30:16 - Sales Tactics and Community Revenue 35:37 - Closing Deals and Personalized Content 40:53 - Investing and Scaling Back-End Revenue 46:30 - Fame vs. Influence in Marketing 51:04 - Biological and Strategic Dating Dynamics 58:43 - Evolution, Social Standards, and Economics 01:10:45 - Business Risks of Political Commentary 01:18:06 - Generational Wealth Transfers and Growth ————————————————————

Weekly Kingdom Outlook Episode 225-Daily Prayer As we progress, the progression of prayer will encompass our daily prayers, abiding prayers, and eventually the courtroom atmosphere. I intend to demonstrate the various aspects of prayer during these three weeks as we mature in the Lord and receive greater authority.

durée : 00:11:13 - Le Fil de l'histoire - par : Stéphanie DUNCAN - Durant l'été 1941, rien ne semble pouvoir arrêter la formidable progression des troupes allemandes en Union soviétique. Au bout seulement de trois semaines, elles occupent les pays baltes, la Biélorussie, l'Ukraine et presque toute la Moldavie. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Hour 2 of the Chris Hand Show | Monday 02-09-26 We're diving into the world of the Olympics and the Super Bowl, where patriotism and politics collide. Chris discusses the halftime show, Olympic athletes' statements, and the Save Act. We hear from Olympic skier Hunter Hess, who sparked controversy with his comments on representing America, and figure skater Amber Glenn, who spoke out about the LGBTQ+ community. The conversation also touches on voter ID laws, with a surprising twist from Senator John Fetterman. See omnystudio.com/listener for privacy information.

  ⏰

A great fartlek and progressive threshold session to improve your running. Plus, the components that should be part of an effective run program, even though they're not necessarily classified as “run sessions”. Part of this episode is original content, and part of it is a preview of the full episode "Power Rankings - Our top-5 run sessions to improve triathlon running performance" (release date 5th of February 2026). TOPICS COVERED IN THIS EPISODE: Mikael's favourite Fartlek run Jack's descending threshold sessionWhy and how to do strides and hill sprintsWhen is running off the bike a good idea? (Even though a lot of the time it isn't a good idea, and it's probably overused in triathlon)How hilly is a “hilly endurance run”? LEARN MORE ABOUT SCIENTIFIC TRIATHLON: The Scientific Triathlon website is the home of That Triathlon Show and everything else that we doContact us through our contact form or email me directly (note - email/contact form messages get responded to much more quickly than Instagram DMs)Subscribe to our NewsletterFollow us on InstagramLearn more about our coaching, training plans, and training camps. We have something to offer for everybody from beginners to professionals. HOW CAN I SUPPORT THAT TRIATHLON SHOW (FOR FREE)? I really appreciate you reading this and considering helping the show! If you love the show and want to support it to help ensure it sticks around, there are a few very simple things you can do, at no cost other than a minute of your time. Subscribe to the podcast in your podcast app to automatically get all new episodes as they are released.Tell your friends, internet and social media friends, acquaintances and triathlon frenemies about the podcast. Word of mouth is the best way to grow the podcast by far! Rate and review the podcast (ideally five stars of course!) in your podcast app of choice (Spotify and Apple Podcasts are the biggest and most important ones).Share episodes online and on social media. Share your favourite episodes in your Instagram stories, start a discussion about interesting episodes on forums, reference them in your blog or Substack. NordVPN - EXCLUSIVE NordVPN Deal ➼ https://nordvpn.com/TRIATHLONTry it risk-free now with a 30-day money-back guarantee Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On episode 732 of the 40+ Fitness podcast, Coach Allan welcomes strength and fitness legend Dan John to the show, a man whose decades of experience span from elite athletics to coaching and academia. In this episode, Coach Allan, fresh off celebrating his 60th birthday, shares a hard-hitting statistic: only 22% of people actually follow the bare minimum guidelines for strength training. This sets the stage for a powerful conversation on why resistance training isn't just a good idea. It's absolutely vital for anyone over 40 who wants to maintain their health, function, and independence into their later years. Dan John unpacks his concept of "everyday strength," the kind of lasting fitness that lets you handle anything life throws your way, from carrying all your groceries in one trip to chasing after grandkids without missing a beat. Together, Coach Allan and Dan John break down how your focus should evolve with age: building foundational strength in midlife, prioritizing muscle mass, joint mobility, and regular walking as you move through your 50s, 60s, and beyond. Tune in for actionable tips, insights on how to structure your training for the long haul, and the wisdom you need to invest in your future health.   Time Stamps: 04:29 Embracing Strength and Growth 09:15 Strength Retention Over Time 11:20 Everyday Strength and Progression 13:51 Focus on Joint Mobility 18:04 Planning for Independence and Mobility 21:47 Longevity vs. Modern Enhancements 23:53 Pot Belly and Happiness Link 29:22 Walking Routine and Steps 30:43 Why Walking Beats High-Intensity Workouts 35:15 Muscle Beach Memories, 1977 38:39 Steps, Meals, and Caloric Balance 41:44 Embrace the Obvious for Wellness 42:58 Visit Dan John University - https://danjohnuniversity.com 

In this episode, I'm joined by Nick Smoot to revisit several classic topics pulled from old articles he wrote on my website. We talk about whether static stretching is actually overrated, why progression still matters most for results, why not everyone needs to track their food, and how to think about cardio for fat loss.

Most fitness businesses don't fail because of effort.They fail because the system was never designed to scale.If you're still:• “Trying harder”• Tweaking ads without structure• Relying on motivation instead of infrastructure…this video will expose exactly why that approach breaks.Inside this breakdown, we dismantle the biggest lie in the fitness industry: